Head, The Cancer Immunotherapy Lab
The Tel-Aviv Medical Center
Ilan Volovitz heads a lab that combines basic research in cancer immunotherapy with clinical translation.
A cell therapy approach developed in the lab called "Split Immunity" for treatment of glioblastoma has completed a First in Human trial in the department of Neurosurgery at the Tel Aviv medical center.
The approach has been recently approved as a phase I/II trial that is soon to open.
Another technology developed in the lab enabling multi-layered intratumoral cellular monitoring was recently commercialized into a company focused on the discovery of predictive biomarkers for cancer immunotherapy.